Takeda Pharmaceutical Company Limited 보도자료

6월 4일 11:40

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) - a chemotherapy regimen - i...

6월 2일 11:25

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), w...

5월 28일 08:44

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Takeda (TSE:4502/NYSE:TAK ) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking research with a focus on emerging scientific lead...

5월 18일 12:55

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda (TSE: 4502/NYSE:TAK ) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 ...

5월 18일 12:55

뉴잉글랜드 의학저널, 1형 기면증 환자 대상 경구용 오렉신 수용체 2 작용제 오베포렉스턴(TAK-861) 2b상 임상시험 데이터 발표

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK )는 오늘, 뉴잉글랜드 의학저널(New England Journal of Medicine) 이 1형 기면증(NT1) 환자 대상 오베포렉스턴(TAK-861)의 임상 2b상 시험 데이터를 게재했다고 발표했다. 오베포렉스턴은 NT1을 유발하는 ...

5월 8일 17:06

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Takeda (TOKYO:4502/NYSE:TAK ) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating...

3월 4일 10:49

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized...

1월 31일 13:12

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda (TOKYO:4502/NYSE:TAK ) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief execu...

1월 30일 15:50

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14...

1월 2일 09:03

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda (TSE:4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or...

2024년 12월 13일 09:01

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Takeda (TSE:4502/NYSE:TAK ) will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market o...

2024년 12월 4일 10:45

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Takeda (TSE:4502/NYSE:TAK ) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, H...

2024년 11월 3일 10:30

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full ...

2024년 11월 3일 10:30

다케다, FY2024 상반기 실적 호조 발표 및 연간 전망 상향 조정

다케다(도쿄증권거래소: 4502/뉴욕증권거래소: TAK )가 FY2024 상반기(2024년 9월 30일 마감 6개월) 실적을 발표하고 성장 및 제품 출시 분야의 지속적인 모멘텀이 성장을 주도하고 있다고 오늘 밝혔다. 회사는 연간 전망 및 경영 지침을 상향 조정하여 예상보다 강...

2024년 9월 25일 09:03

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK ) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vasc...

2024년 9월 20일 09:49

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda (TSE:4502/NYSE:TAK ) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024...

2024년 9월 20일 09:45

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and m...

2024년 9월 20일 09:45

다케다, 5개의 신규 글로벌 기업 사회적 책임 파트너십에 3200만달러 이상을 제공해 93개국에서 보건 영향력 확대

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 오늘 5개 신규 글로벌 기업 사회적 책임(Corporate Social Responsibility, CSR) 파트너에게 46억엔(약 3200만달러)을 투입했다. 이는 전 세계 저소득 및 중소득 국가(low and middle-income countries)...

2024년 8월 8일 15:25

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cT...

2024년 8월 1일 14:00

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda (TOKYO:4502/NYSE:TAK ) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Growth & Launch Products driving Core growth at CER and more than offsetting reve...

2024년 8월 1일 14:00

다케다, 2024 회계연도 1분기 실적 발표… 성장 및 출시 제품에 의한 강력한 실적, 유망한 후기 단계 파이프라인의 발전

다케다(Takeda)(TOKYO:4502/NYSE:TAK )가 7월 31일(현지 시간) 성장 및 출시 제품의 지속적인 모멘텀이 일정환율(Constant Exchange Rate, CER) 기준으로 핵심 성장을 주도하고 이전 회계연도에 발생한 상당한 독점권 손실로 인한 매출 영향을 상쇄하고도 남는 2024 ...

2024년 6월 27일 14:20

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Ta...

2024년 6월 27일 14:20

다케다, 새로운 이사 임명 발표

다케다(Takeda)(TOKYO:4502/NYSE:TAK)가 오사카에서 개최된 제148차 정기 주주총회에 이어 이사회 회의와 감사 및 감독 위원회 회의에서 결정된 새로운 이사 선임을 발표했다. 다케다 이사회는 총 14명 중 11명이 사외이사로 재직하고 있어 투명성과 객관성을 확보하...

2024년 6월 25일 09:26

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda (TSE:4502/NYSE:TAK ) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing ant...

2024년 6월 23일 13:54

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Takeda (TSE:4502/NYSE:TAK ) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic pri...

Takeda Pharmaceutical Company Limited 보도자료

Takeda Pharmaceutical Company Limited 보도자료

Takeda Pharmaceutical Company Limited

회사 보도자료 구독